Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Urinary Bladder Neoplasms 1Newly Diagnosed Glioblastoma 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

efineptakin alfa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Newly Diagnosed Glioblastoma × efineptakin alfa × Clear all
NCT04065087 2022-03-17

Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma

Genexine, Inc.

Phase 1/2 Withdrawn
CNS

Newly Diagnosed Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡